key: cord-0698997-jylhyqnp
authors: Pedrazini, Maria Cristina; da Silva, Mariliza Henrique
title: Pityriasis rosea‐like cutaneous eruption as a possible dermatological manifestation after Oxford‐AstraZeneca vaccine: Case report and brief literature review
date: 2021-09-25
journal: Dermatol Ther
DOI: 10.1111/dth.15129
sha: c4d3f64ef80cf30c76944358cba83ae3a66b98b9
doc_id: 698997
cord_uid: jylhyqnp

Pityriasis rosea (PR) has been manifested in patients suffering from COVID‐19 as well as after vaccine protocols against SARS‐CoV‐2. It has a possible association with the HHV‐6B virus (roseola infantum) and can be controlled by antivirals such as acyclovir as well as by the amino acid l‐Lysine that showed a positive result in reducing the number of lesions and healing time. The aim of this study was to report a case of PR after a second dose of Oxford‐AstraZeneca, the adopted therapy and a brief literature review. A 53‐year‐old woman, phototype II, presented an erythematous lesion in the posterior right thigh 15 days after the second dose of Oxford‐AstraZeneca vaccine. Eight days after the initial injury, new injuries appeared in the calf, buttocks and thighs. The diagnosis was PR with a 5‐week eruption cycle. The treatment consisted of the use of l‐Lysine, 3 grams loading dose and 500 mg for 30 days and moisturizing/healing lotion, starting 14 days after the herald patch. After the 5th week of the disease cycle, there were no new eruptions and the repair cycle continued for up to 8 weeks leaving some residual skin spots. It is concluded that the patient may be a carrier a latent virus, HHV‐6, and the vaccine administration with immune system stimulation, would have activated the possible virus causing PR. l‐Lysine helped to control the manifestation by limiting the number of lesions and their location, which were restricted to the legs, thighs and buttocks.

The ChAdOx1nCoV-19 (AZD1222) vaccine was developed at Oxford University, consists of a replication-deficient chimpanzee adenoviral gene (ChAdOx1) and contains the antigen gene, a SARS-CoV-2 structural surface glycoprotein (spike protein nCoV -19) . In adults over 18 years of age, it was found to be effective against COVID-19 with a good safety profile in interim analyzes of ongoing clinical trials. 3 This non-replicating viral vector, the modified adenovirus, makes the immune system identify the spike protein, promoting a protective response against infection in case of exposure to SARS-CoV-2. 9 What has been observed is that these vaccines have shown adverse effects in some people and among them are pain at the injection site, fever, headache, nausea and vomiting. 1, 2 In some individuals there were skin reactions and among them there were reports of pityriasis rosea, 52 cases between January and June 2021. 10 Pityriasis rosea (PR) is a benign skin disease, erythematoussquamous papules distributed on the trunk and extremities that starts, in most cases, with a single, oval, pink lesion called "mother patch" or "herald patch" showing a centrifugal growth measuring 2-10 cm in diameter. This lesion can remain isolated and single for 1 or 2 weeks when new secondary lesions of 0.5 to 1.5 cm appear in the thorax, abdomen, back and proximal extremities of the limbs. The initial phase is characterized by salmon-colored plaques, in the clinical phase a scaling begins and finally, the healing process is characterized by the lightening of the spots. [11] [12] [13] [14] The evolution can vary from 6 to 8 weeks and can last from 3 to 6 months. Regression is spontaneous, leaving changes in skin color that disappear over the months. However, despite self-resolution, some dermatologists prescribe drugs such as antihistamines and corticosteroids, as well as sunbathing, which help when itching and with residual skin spots. 11, 14 Regarding etiology, fungi, bacteria and viruses were suggested, and the possibility of the involvement of autoimmune processes and pharmacological idiosyncrasies was also pointed out, however, some characteristics suggest that it is an infectious process which more recent trends attribute to a virus. 11, 12, [14] [15] [16] Studies have shown a strong association of PR with human herpesviruses (HHV-6 and HHV-7) as an etiological factor 12,14-16 and with the suspicion of this viral involvement, therapy with antivirals such as acyclovir was indicated 15, 17, 18 as well as alternative therapy with L-Lysine amino acid 14, 19 that showed positive results in reducing healing time as limiting the number of lesions when started at the beginning of the dermal manifestation, as soon as possible, still the first 2 weeks, in the viral multiplication phase. 14, 19, 20 It is noteworthy that L-Lysine may also be associated with an increases excretion of an essential amino acid for some viruses initial replication, the L-Arginine. 21,22 Therefore, the use of L-Lysine together with a reduction in the intake of L-Arginine, present in supplements and foods such as chocolate, peanuts, nuts, gelatin, cashew nuts, corn, coconut, oats, coffee and raisins, can make difficult for the virus to enter in the cell remaining it in virion form limiting the evolution of the disease. 14, 20 Currently, PR has been associated as a dermal manifestation of SARS-COV-2 (COVID-19). 16, 23, 24 Although the diagnosis of PR has become more common during the COVID-19 pandemic, it is still unclear whether this cutaneous manifestation is secondary to the direct invasion of SARS-CoV-2, because in PR lesions the virus protein was found, whether it is due to reactivation of latent viruses such as HHV-6/7 and HHV-4 or EBV (Epstein-Barr virus) by the immunomodulatory capacity of COVID-19 to reactivates them or whether due to other factors. 16 Among the other factors is PR as a secondary reaction after vaccine protocols [25] [26] [27] [28] [29] [30] [31] being an important alert to dermatologists and other professionals in the area to assist in diagnosis.

In the midst of COVID-19 pandemic with several vaccine protocols being applied, the aim of this study was to report a case of RP after a second dose of Oxford-AstraZeneca, the adopted therapy and a brief literature review on the subject. 

The clinical case reported shows a skin reaction after a vaccine against the COVID-19 virus, diagnosed as PR despite the atypical condition, located only in the lower region of the trunk and lower limbs.

Dermoscopy has become an essential diagnostic tool in many diagnostic conditions in dermatology, such as melanocytic nevus lesions 32 however, in relation to dermoscopy in inflammatory skin lesions, knowledge is limited and there are few studies on the diagnostic technique of PR. Some authors investigated the dermoscopic features in PR lesions and the most common finding was collarette scale, which is also clearly visible to the naked eye. It was reported that many features that were not previously described for RP could be seen with the dermoscope, including irregular linear vessels, blood spots, brown blood cells and no brown structure, concluding that this exam can provide important clues to the diagnosis, especially in the atypical presentation of the entity. 33 A punch biopsy could also be useful to check whether typical histological features of PR were present but both, dermoscopy or biopsy, were not indicated by the dermatologist or infectologist. They were categorical in the diagnosis of PR after collecting the clinical history and observing the injuries evolution.

Diagnosis of typical PR, with Christmas tree-shaped truncal involvement, is not difficult for doctors like dermatologists or general pediatrician however, its atypical presentations can be challenging even for these professionals. 13 In the typical form diagnostic doubts hardly arise but, as 20% of the cases present atypically, this can favor is similar to what is observed in patients infected with COVID-19, also leading to other viral reactivations. 30 There is also the hypothesis of a less specific secondary reaction to the immune response as seen with other unrelated vaccines. 11, 30 In a state of altered immunity, HHV-6/7 reactivation may result from a T cell-mediated skin-oriented reaction in an atypical presentation of self-limited PR. 27 HHV-6 has two distinct variants with different immunological, biological and genetic properties. HHV-6A is considered more cytolytic with a higher level of virulence, HHV-6B would cause sudden exanthema (Roseola infantum). 14, 38 What would explain a possible cause of PR in this case report is the epidemiological factor. The daughter had roseola in 2008, becoming a latent carrier of HHV-6B and in 2017 she reactivated the virus with the PR condition. As the mother, patient in this case report, was In the last years, several treatment options have been proposed to combat the clinical manifestations of PR. In addition to topical antihistamines and corticosteroids, 11, 14 antivirals such as acyclovir can also be indicated to control dermal symptoms, pruritus and to aid in the remission of PR by acting in the suppression of viral replication 17,18 however, for this to happen, it needs to be started in the first few days. 15 Another alternative treatment for PR would be the use of L-Lysine 3 grams for up to 3 days, loading dose, followed by 500 mg/ day for 30 days 14, 19 also starting in the first days of the manifestation of PR. 14 The antiviral potential of L-Lysine may be associated with the fact that this amino acid increases the excretion of L-Arginine by the kidney and intestine, decreasing its concentration and consequently its action on protein synthesis by the virus, preventing replication, 14, 21 and that the lesions do not progress to the active clinical phase, disappearing in the prodromal phase. 14, 20 To avoid the reactivation of latent viruses of the herpesvirus family is important the lysine/arginine balance in the diet. To control the multiplication of the virus, when active, an increase in the supply of L-Lysine and a reduction in the intake of L-Arginine are indicated. 14, 20 The fact that the patient in this report started L-Lysine with reduced L-Arginine intake, 14 days after the medallion appeared, may have contributed to the reduced number of lesions limited to the thighs (5), calf (1), posterior knee (1), and buttocks (5) .

It has been suggested that during the COVID-19 pandemic, largescale epidemiological studies should be conducted to elucidate whether there is in fact a relationship between vaccination regimens and the reactivation of latent viruses. 37 This mass investigation would be important to see whether this reactivation could be a coincidence or a consequence, either in relation to reactivation by infection or by the anti-SARS-CoV-2 vaccines.

Overall, the data support that skin reactions post-immunizing agents anti-COVID-19 are generally non-hazardous and self-limiting and should not discourage vaccination. So far, there are no reports of patients who have experienced anaphylaxis or other serious adverse events. 28 Health professionals should be aware of these adverse reactions to the vaccine, carry out the appropriate management. 29 and reinforce with patients about the potential benefits of receiving immunizations, even if small reactions occur. 28 

It is concluded that even if there are dermal reactions after vaccination against COVID-19, as they are not dangerous, patients should be advised to receive necessary doses, regardless of the immunizing agent. PR is a benign, self-limiting disease, with spontaneous resolution and without a definitive treatment protocol, but with the supposed viral association, antivirals can be indicated and among them there is the proposal to use the amino acid L-Lysine with positive results.

Health professionals should be aware of the possibility of PR as a symptom of COVID-19 as well as a reaction to vaccines and provide the necessary counseling.

The authors declare no potential conflict of interest.

Maria Cristina Pedrazini: researcher responsible for monitoring the clinical case, data collection, bibliographic review and writing of the article. Mariliza Henrique da Silva: researcher responsible for diagnostic confirmation, technical information, bibliography reviews and support in writing; final article review. All authors read and approved the final draft.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

https://orcid.org/0000-0002-7649-6626

Mariliza Henrique da Silva https://orcid.org/0000-0003-2194-8805

A review of the Progress and challenges of developing a vaccine for COVID-19

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia

Covid-19: FDA panel votes to approve Pfizer BioNTech vaccine

Coronavirus vaccine tracker

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomized, placebo-controlled, phase 3 trial in Turkey

How the Oxford-AstraZeneca covid-19 vaccine was made

All UK -Spontaneous reports received between 04/01/21 and 16/06/21 for COVID-19 vaccine Oxford University/AstraZeneca. COVID-19 vaccine AstraZeneca analysis. Government of United Kingdom

Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature

An atypical presentation of Pityriasis Rosea localized to the extremities

Pityriasis Rosea: an updated review

L-lysine therapy to control the clinical evolution of pityriasis rosea: clinical case report and literature review

The efficacy of oral acyclovir during early course of pityriasis rosea: a systematic review and meta-analysis

SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19

Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis

Interventions for pityriasis rosea

Lysine for pityriasis rosea: is it a new treatment option?

The effect of l-lysine in recurrent herpes labialis -pilot study with an 8-year follow up

Prophylaxis against herpes simplex virus reactivation in patients with facial burns: a potential role for L-lysine

Recurrent herpes zoster ophthalmicus in a young, healthy individual taking high doses of L-Arginine

Pityriasis rosea as a cutaneous manifestation of COVID-19 infection

Pityriasis rosea Gibert type rash in an asymptomatic patient that tested positive for COVID-19

Pityriasis rosea following influenza (H1N1) vaccination

Uncommon presentation of Pityriasis Rosea after yellow fever inoculation

An atypical case of pityriasis rosea gigantea after influenza vaccination

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registrybased study of 414 cases

Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination

Pityriasis rosea after mRNA COVID-19 vaccination

Pityriasis rosea developing after COVID-19 vaccination

The fast clinical evolution of a spitz nevus: three-years follow-up of a child

Dermoscopic profile of pityriasis rosea

Clinical variants of pityriasis rosea

Pitiríase rosea

Pityriasis rosea and pityriasis rosealike eruptions: how to distinguish them?

Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence?

Evidence of active herpesvirus 6 (variant-A) infection in patients with lymphadenopathy in Belém

The clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease

Cutaneous reactions after SARS-COV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases

Pityriasis rosea following Cor-onaVac COVID-19 vaccination: a case report

Pityriasis rosea-like cutaneous eruption as a possible dermatological manifestation after Oxford-AstraZeneca vaccine: Case report and brief literature review